Kevin McLoughlin has always been fascinated by the intersection of computing and biology. His LLNL career encompasses award-winning microbial detection technology, a COVID-19 antiviral drug design pipeline, and work with the ATOM consortium.
LLNL researchers and collaborators have developed a highly detailed, ML–backed multiscale model revealing the importance of lipids to RAS, a family of proteins whose mutations are linked to many cancers.
LLNL will lend its expertise in vaccine research and computing resources to the Human Vaccines Project consortium to aid development of a universal coronavirus vaccine and improve understanding of immune response.
Computational biology is using HPC to rapidly design and develop ways to treat cancer and COVID. LLNL researcher Felice Lightstone discusses ATOM (Accelerated Therapeutic Opportunities in Medicine) in this edition of SC21 TV.
From studying radioactive isotope effects to better understanding cancer metastasis, the Laboratory’s relationship with cancer research endures some 60 years after it began, with historical precedent underpinning exciting new research areas.
COVID-19 HPC Consortium scientists and stakeholders met virtually to mark the consortium’s one-year anniversary, discussing the progress of research projects and the need to pursue a broader organization to mobilize supercomputing access for future crises.